Trajan (ASX:TRJ) manufactures precision measurement tools in its own facilities for a wide range of clientele, which includes laboratories, pathologists, and food and environmental analysts. 

The company is a critical player in precision measurement in the analytical science industry, which includes precision consumable products, devices and solutions for biological, food, environmental and human health related testing. The group is pursuing an overt acquisition strategy to increase the breadth of its markets and depth of product lines.

Trajan’s relationships with its OEM partners range from data analysis, collaborative technology developments, to the design and supply of analytical components embedded in their instrumentation, customised consumable products and automation workflow solutions. The company also has relationships with pathology groups and big pharma.

Investment summary

Trajan has a resilient balance sheet, with reducing debt and positive cashflow. It's acquisition led growth has boosted its capabilities, albeit with high capital and merging costs, and it does not provide dividends, reinvesting into its balance sheet.

Current Operations

Trajan is a global organization of more than 650 people, with six manufacturing sites across the US, Australia, Europe and Malaysia, and operations in Australia, the US, Asia, and Europe. It divides its business into two parts.

1. Analytical products and devices creates products to assess and measure a variety of subjects and phenomena such as food, biology and the environment.

2. Life science solutions uses partnerships to action on research, governance and products to improve wellbeing in biology food and environments. Trajan is benefitted from its acquisition led approach in this goal, which generates further opportunities, to create more life sciences products.

Want to see other interesting ASX Healthcare Shares stocks?